Recent findings from Karolinska Institutet indicate that patients diagnosed with both Alzheimer’s disease and atrial fibrillation may experience slower cognitive decline when treated with newer oral anticoagulants. The study, published in the European Heart Journal, observed over 7,000 patients tracked through the Swedish Register for Cognitive Disorders.
Researchers compared individuals taking NOACs against those using warfarin or no anticoagulant medication at all. Results showed that patients on NOACs experienced a slower rate of cognitive loss, measured by a difference of approximately 0.2 points annually on the Mini-Mental State Examination. While this margin is modest in the short term, the cumulative effect over several years remains a subject of clinical interest for long-term geriatric care.
The study also assessed broader health outcomes for this specific patient population. Patients treated with NOACs demonstrated lower risks regarding mortality, stroke, blood clots, and bone fractures compared to the control group. While warfarin also correlated with reduced risks for strokes and clots, it was linked to a higher incidence of major bleeding compared to the newer anticoagulant treatments.
As this was an observational study, the research team notes that it does not confirm a direct causal relationship. Factors influencing medication choice and potential changes in prescription during the follow-up period may have impacted the results. However, the data provides a strong signal for further investigation into how blood-thinning therapies impact brain health in individuals already living with dementia. Geriatric specialists look to these results to better understand how cardiovascular treatments can influence neurological progression.